Overcoming barriers to unlock the therapeutic potential of saroglitazar for the management of metabolic dysfunction-associated steatotic liver disease.

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a severe and multifaceted condition that significantly impacts liver health and overall metabolic well-being. Despite its prevalence, effective pharmacological options for MASLD remain limited, and treatment largely depends on lifestyle modifications. Saroglitazar, a dual peroxisome proliferator-activated receptor (PPAR) alpha and gamma agonist, has demonstrated promising efficacy in managing MASLD by improving lipid metabolism, reducing liver fat accumulation, and enhancing insulin sensitivity. However, its clinical adoption and widespread utilization are hindered by several challenges, ranging from limited clinical data to regulatory and awareness barriers. This article explores the obstacles to saroglitazar acceptance, evaluates its therapeutic potential, and discusses strategies to integrate it into mainstream MASLD management.